Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments (2016 - 2017)

Ocular Therapeutix has reported Change in Acquisitions & Divestments over the past 3 years, most recently at $3.0 million for Q3 2017.

  • For Q3 2017, Change in Acquisitions & Divestments fell 79.57% year-over-year to $3.0 million; the TTM value through Dec 2017 reached $38.2 million, down 52.65%, while the annual FY2017 figure was $38.2 million, 52.65% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2017 was $3.0 million at Ocular Therapeutix, down from $22.7 million in the prior quarter.
  • Over five years, Change in Acquisitions & Divestments peaked at $30.0 million in Q3 2015 and troughed at $3.0 million in Q3 2017.
  • A 3-year average of $18.2 million and a median of $16.0 million in 2016 define the central range for Change in Acquisitions & Divestments.
  • Biggest five-year swings in Change in Acquisitions & Divestments: rose 6.67% in 2016 and later plummeted 79.57% in 2017.
  • Year by year, Change in Acquisitions & Divestments stood at $15.0 million in 2015, then increased by 6.67% to $16.0 million in 2016, then plummeted by 81.25% to $3.0 million in 2017.
  • Business Quant data shows Change in Acquisitions & Divestments for OCUL at $3.0 million in Q3 2017, $22.7 million in Q2 2017, and $12.5 million in Q1 2017.